Alphabet's (GOOG, GOOGL) artificial intelligence-based drug discovery unit Isomorphic Labs said Monday it raised $600 million in its first external funding round to develop its AI drug design engine and support drug candidates into clinical testing.

The investment, led by Thrive Capital with participation from GV and Alphabet, is expected to support AI research, the company said, adding that it has internal drug discovery programs in oncology and immunology, as well as collaborations with Eli Lilly (LLY) and Novartis (NVS).

Isomorphic Labs said it also plans to expand its workforce.